Who is sponsoring NCT04316377?

NCT04316377 is sponsored by University Hospital, Akershus.

What drugs are being tested in NCT04316377?

Interventions in NCT04316377: Hydroxychloroquine Sulfate.

What condition does NCT04316377 study?

NCT04316377 studies Corona Virus Infection.

Is NCT04316377 still recruiting?

NCT04316377 is currently status unknown. Last updated 5 June 2020.

Last reviewed 2020-06-05 · How we verify

NCT04316377: NO COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Norwegian Coronavirus Disease 2019 Study

Status unknown Phase 4 Last updated 5 June 2020

What this trial tests

Phase 4 trial testing Hydroxychloroquine Sulfate in Corona Virus Infection in 53 participants. Status unknown.

Timeline

25 March 2020

Primary endpoint
25 May 2020

3 March 2025

Quick facts

Lead sponsor	University Hospital, Akershus
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	53
Start date	25 March 2020
Primary completion	25 May 2020
Estimated completion	3 March 2025
Sites	1 location across Norway

Drugs / interventions tested

Hydroxychloroquine Sulfate (hydroxychloroquine-pill) — full drug profile →

Conditions studied

Corona Virus Infection — all drugs for Corona Virus Infection →

Sponsor

University Hospital, Akershus

Who can join

18 and older, any sex, with Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the current proposal, the investigators aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission. Patients will be randomized in a 1:1 fashion to standard of care or standard of care with the addition of therapy with chloroquine.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.
Driggin E, Madhavan MV, Bikdeli B, Chuich T, et al · · 2020 · cited 1272× · PMID 32201335 · DOI 10.1016/j.jacc.2020.03.031
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.
Ulrich H, Pillat MM. · · 2020 · cited 291× · PMID 32307653 · DOI 10.1007/s12015-020-09976-7
A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).
Kakodkar P, Kaka N, Baig MN. · · 2020 · cited 255× · PMID 32269893 · DOI 10.7759/cureus.7560
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, et al · · 2021 · cited 217× · PMID 33859192 · DOI 10.1038/s41467-021-22446-z
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Arshad U, Pertinez H, Box H, Tatham L, et al · · 2020 · cited 115× · PMID 32438446 · DOI 10.1002/cpt.1909

Verify or expand the search:

Other trials of Hydroxychloroquine Sulfate

Trials testing the same drug.

NCT06519617 — Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage · Phase 2 · enrolling by invitation
NCT04340349 — Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals · EARLY_PHASE1 · unknown
NCT04380818 — Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 · NA · unknown
NCT04386057 — LY3214996 +/- HCQ in Pancreatic Cancer · Phase 2 · completed
NCT04361461 — Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) · Phase 3 · withdrawn

Other recruiting trials for Corona Virus Infection

Currently open trials in the same condition.

NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT05684549 — Coronavirus Infection (COVID-19) and Radical Surgery in Patients With Early-stage Lung Cancer · active not recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
NCT04371315 — Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting

Other University Hospital, Akershus trials

Trials by the same sponsor.

NCT06865027 — The Effect of Arterial Carbon Dioxide Levels on Cerebral Blood Flow and Cerebral Autoregulation in the Steep Trendelenbu · NA · enrolling by invitation
NCT06721754 — Diabetes Related Foot Ulcers with Negative Pressure Wound Therapy · NA · recruiting
NCT06731985 — The Follow-up After Shorter Tapes Study. Effectiveness and Safety of Shorter Trans-obturator Tapes. · recruiting
NCT06576752 — Management of Patients with Heart Failure At Home After Hospital Discharge · NA · recruiting
NCT06032715 — Brief Intervention for Sleep Medication Misuse Among Elderly · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04316377 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Akershus
Last refreshed: 5 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04316377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing